Integrated System Streamlines Pre-Analytical Workflow for Molecular Testing
Posted on 15 Apr 2026
Pre-analytical variation remains a leading source of inconsistent molecular test results and added costs, particularly when laboratories rely on multiple instruments and protocols. Standardizing nucleic acid extraction, concentration, and quantification can reduce sample-to-sample variability across workflows, including measurable residual disease (MRD) testing and liquid biopsy. A newly launched system unifies these steps on a single automated instrument to streamline sample preparation and improve consistency.
Invivoscribe has introduced the PrepQuant System, an integrated sample preparation platform developed in collaboration with Hitachi High-Tech Corporation. The launch centers on standardizing the pre-analytical phase to help reduce costs and eliminate a primary source of inconsistency in molecular testing. The company positions the system for broad use in precision diagnostics across diverse laboratory settings. The platform is presented as a way to simplify workflows while maintaining reproducibility from start to finish.
The PrepQuant System integrates nucleic acid extraction, concentration, and quantification within a single automated instrument. It is assay-agnostic and generates highly concentrated genomic DNA and cell-free DNA (cfDNA) suitable for next-generation sequencing (NGS), quantitative polymerase chain reaction (qPCR), and digital PCR (dPCR) assays. By consolidating multiple steps onto one platform, the system is described as reducing laboratory operating costs, minimizing sample variability, and saving bench space while optimizing test results.
The system is designed and validated for use with blood, plasma, and bone marrow specimens, with development underway for additional specimen types. Invivoscribe plans to unveil the platform at the American Association for Cancer Research (AACR) Annual Meeting, taking place in San Diego, California from April 19–22. The company is issuing quotes now and anticipates first commercial shipments in North America in August 2026, followed by European availability in January 2027. Additional kit releases are anticipated by the end of 2026 to expand the system’s menu.
“The PrepQuant System represents a significant advancement in our commitment to standardize the entire testing process, starting with the pre-analytical workflow. By integrating extraction, concentration, and quantification in one platform, we reduce variability to help ensure generation of consistent, high-quality test results. This is particularly important in the era of precision medicine, where reliability of MRD and liquid biopsy results depend markedly on the quality and consistency of the starting material,” said Jeff Miller, CEO and CSO of Invivoscribe.
Related Links
Invivoscribe
